We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-8.7%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$449M
AUM Growth
-$122M
Cap. Flow
-$33.8M
Cap. Flow %
-7.52%
Top 10 Hldgs %
73.91%
Holding
54
New
15
Increased
8
Reduced
14
Closed
9

Top Buys

Rank Stock Value
1
SNWV
SANUWAVE Health Inc
SNWV
+$31.9M
2
IMNM icon
Immunome
IMNM
+$14.5M
3
LQDA icon
Liquidia Corp
LQDA
+$8.2M
4
ANIK icon
Anika Therapeutics
ANIK
+$6.57M
5
LRMR icon
Larimar Therapeutics
LRMR
+$6.05M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$58M
2
OCUL icon
Ocular Therapeutix
OCUL
+$21.1M
3
JSPR icon
Jasper Therapeutics
JSPR
+$8.55M
4
NAMS icon
NewAmsterdam Pharma
NAMS
+$8.35M
5
TRVI icon
Trevi Therapeutics
TRVI
+$7.26M

Sector Composition

Rank Sector Weight
1 Healthcare 97.58%
2 Miscellaneous 2.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPIX
26
DELISTED
ESSA Pharma
EPIX
$3.49M 0.78%
2,209,998
– –
ZNTL icon
27
Zentalis Pharmaceuticals
ZNTL
$367M
$3.16M 0.7%
1,985,000
+217,500
+12% +$469K
CRGX
28
DELISTED
CARGO Therapeutics
CRGX
$2.71M 0.6%
666,503
-83,497
-11% -$559K
ZYME icon
29
Zymeworks
ZYME
$2.07B
$2.08M 0.46%
+175,000
New +$2.39M
BDSX icon
30
Biodesix
BDSX
$300M
$2.02M 0.45%
161,250
-12,000
-7% -$230K
STOK icon
31
Stoke Therapeutics
STOK
$2.1B
$2M 0.44%
300,000
+275,000
+1,100% +$2.56M
MBX
32
MBX Biosciences
MBX
$3.2B
$1.84M 0.41%
+250,000
New +$2.64M
OPTN
33
DELISTED
OptiNose
OPTN
$1.77M 0.39%
+193,039
New +$1.21M
IRD
34
Opus Genetics
IRD
$320M
$1.55M 0.34%
+1,175,000
New +$1.31M
IBIO icon
35
iBio
IBIO
$69.5M
$1.51M 0.34%
375,000
– –
KNSA icon
36
Kiniksa Pharmaceuticals
KNSA
$6.23B
$1.39M 0.31%
+62,501
New +$1.29M
NRIX icon
37
Nurix Therapeutics
NRIX
$2.79B
$1.37M 0.3%
115,000
-263,500
-70% -$4.41M
RZLT icon
38
Rezolute
RZLT
$480M
$1.35M 0.3%
465,000
– –
SGMO
39
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$692K 0.15%
+1,055,000
New +$1.12M
PEPG icon
40
PepGen
PEPG
$213M
$590K 0.13%
420,000
+310,000
+282% +$638K
DERM icon
41
Journey Medical
DERM
$213M
$409K 0.09%
+69,323
New +$341K
VTYX
42
DELISTED
Ventyx Biosciences
VTYX
$219K 0.05%
190,000
-90,000
-32% -$155K
ADGM
43
Adagio Medical Holdings
ADGM
$11.6M
$92.1K 0.02%
110,571
– –
ABCL icon
44
AbCellera Biologics
ABCL
$4.02B
– –
-965,000
Closed -$2.83M
IMTX icon
45
Immatics
IMTX
$1.42B
– –
-165,000
Closed -$1.17M
JSPR icon
46
Jasper Therapeutics
JSPR
$23.3M
– –
-400,000
Closed -$8.55M
LXEO icon
47
Lexeo Therapeutics
LXEO
$409M
– –
-130,000
Closed -$855K
NAMS icon
48
NewAmsterdam Pharma
NAMS
$3.2B
– –
-325,000
Closed -$8.35M
NUVL
49
DELISTED
Nuvalent
NUVL
– –
-58,500
Closed -$4.58M
PCVX icon
50
Vaxcyte
PCVX
$9.1B
– –
-75,000
Closed -$6.14M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2025 Portfolio in Review

As of Q1 2025, Opaleye Management held 54 positions worth $449M, down 21% from $571M the previous quarter. Its ten largest holdings account for 74% of the portfolio.

Opaleye Management withdrew a net $33.8M in Q1 2025, closing 9 positions and reducing 14 holdings. Its most notable exit was Jasper Therapeutics, an estimated $8.55M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in SANUWAVE Health Inc worth $34.4M.

  • Opaleye Management's largest Q1 2025 buy was SANUWAVE Health Inc: 972,002 shares worth $34.4M.
  • Opaleye Management added most to Immunome in Q1 2025, an estimated $14.5M increase.
  • Opaleye Management's biggest Q1 2025 reduction was TG Therapeutics, cutting an estimated $58M.
  • Opaleye Management fully exited Jasper Therapeutics in Q1 2025, selling an estimated $8.55M.
  • Opaleye Management's ten largest holdings make up 74% of its $449M portfolio in Q1 2025.
  • Opaleye Management opened 15 new positions and closed 9 in Q1 2025.
  • Opaleye Management's portfolio value fell 21% quarter-over-quarter to $449M.

Based on Opaleye Management's 13F filing for Q1 2025, filed 15 May 2025.